Disclosures: Robert Wong: Theratechnologies: Grant/Research Support, Durect: Grant/Research Support, Gilead Sciences: Grant/Research Support, Exact Sciences: Grant/Research Support, Theratechnologies: Grant/Research Support, Durect Corporation: Grant/Research Support, Leland Yee: Gilead Sciences: Employee, Yunhao Liu: Gilead Sciences: Employee, Laura Telep: Gilead Sciences, LLC: Employee, Gilead Sciences, LLC: Stock - publicly traded company, Shahed Iqbal: Gilead Sciences, Inc.: Stockholder, Gilead Sciences, Inc.: Stock - publicly traded company, Gilead Sciences, Inc.: Employee, Sarjita Naik: Gilead Sciences: Employee, Gilead Sciences: Stock privately held company, Betty Chiang: Nothing to Disclose, Amanda Singer: Gilead Sciences: Employee, Gilead Sciences: Stock - publicly traded company, Anand Chokkalingam: Nothing to Disclose, Catherine Frenette: Nothing to Disclose 907 DISPARITIES IN PRIMARY BILIARY CHOLANGITIS: A RETROSPECTIVE STUDY USING REAL-WORLD DATA FROM A SINGLE HEPATOLOGY CLINIC IN THE GREATER LOS ANGELES AREA Sabrina Alff 1 Orlinda Ventura 1 Trinity Love Foster-Malave 1 Michel Mendler 1 Edward Mena 2 , 1 California Liver Research Institute, 2 California Liver Reasearch Institiute Background: Primary Biliary Cholangitis (PBC) is an autoimmune disease that leads to cirrhosis

145 The cytokines IL-2 and IL-15 play crucial roles in activating NK cells, with recombinant IL-15 expanding NK cell populations and promoting tumor regression while reducing metastasis
This guide covers supplier comparison, sourcing standards, research applications, reconstitution math, and the compliance framework for Canadian laboratory use
Refresh your look